Detailed list of contraindications for Maribavir/Yitaizhi

Maribavir is a drug used to treat Cytomegalovirus (CMV) infection, especially in patients who have not responded well to other antiviral drugs such as ganciclovir, valganciclovir, cidofovir, or foscarnet. However, like all drugs, maribavir has contraindications and patient groups that require special attention.

First, this medication should not be used by anyone who is allergic to maribavir or any of its ingredients. Anaphylaxis may manifest as hives, swelling of the face, lips, tongue, or throat, and in severe cases may cause difficulty breathing or even be life-threatening. If such a reaction occurs, patients should seek emergency medical help immediately. A history of allergy is one of the most important contraindications to maribavavir. Therefore, you should inform your doctor in detail whether you have any history of drug allergy before use.

In addition, maribavivir should be used with caution in patients with severe hepatic insufficiency. Maribavir is metabolized primarily by the liver; therefore, patients with hepatic impairment may experience increased plasma concentrations of the drug, thereby increasing the risk of toxicity. For such patients, doctors usually adjust the dose or decide whether to use the drug based on their condition.

Although maribavivir plays an important role in treatingCMV infection, it is not suitable for all patients. For example, patients with acute kidney disease need to use it with caution under the guidance of a doctor, because the drug metabolism process may cause adverse effects on the kidneys. The safety of this drug has not been fully established in patients with severely impaired renal function, therefore a detailed assessment of renal function should be performed before initiating treatment.

The use of maribavivir in pregnant and lactating women requires weighing the risks and benefits. Although animal experiments with maribavivir have not shown embryotoxicity, there is still a lack of sufficient clinical data to support its safety during pregnancy. Therefore, maribavivir should generally be avoided in pregnant women unless the situation specifically warrants it.

Reference: https://www.ema.europa.eu/en/documents/product-information/livtencity-epar-product-information_en.pdf